English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
  In vitro efficacy of Artemisia extracts against SARS-CoV-2

Nie, C., Trimpert, J., Moon, S.-Y., Haag, R., Gilmore, K., Kaufer, B. B., et al. (2021). In vitro efficacy of Artemisia extracts against SARS-CoV-2. Virology Journal, 18: 182. doi:10.1186/s12985-021-01651-8.

Item is

Files

show Files
hide Files
:
Article.pdf (Publisher version), 2MB
Name:
Article.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-

Locators

show

Creators

show
hide
 Creators:
Nie, Chuanxiong, Author
Trimpert, Jakob, Author
Moon, Soo-Yeon1, Author              
Haag, Rainer, Author
Gilmore, Kerry1, Author              
Kaufer, Benedikt B., Author
Seeberger, Peter H.2, Author              
Affiliations:
1Kerry Gilmore, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society, ou_1863304              
2Peter H. Seeberger - Automated Systems, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society, ou_1863306              

Content

show
hide
Free keywords: Artemisia annua, Artemisia afra, antivirals, COVID-19, Covid-organics, Feline coronavirus (FCoV), SARS-CoV-2
 Abstract: Traditional medicines based on herbal extracts have been proposed as affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Teas and drinks containing extracts of Artemisia annua and Artemisia afra have been widely used in Africa in efforts to prevent and fight COVID-19 infections. We sought to study the ability of different A. annua and A. afra extracts and the Covid-Organics drink produced in Madagascar to inhibit SARS-CoV-2 and feline coronavirus (FCoV) replication in vitro. Several extracts as well as Covid-Organics inhibit SARS-CoV-2 and FCoV replication at concentrations that did not affect cell viability. It remains unclear whether peak plasma concentrations in humans can reach levels needed to inhibit viral replication following consumption of teas or Covid-Organics. Clinical studies are required to evaluate the utility of these drinks for COVID-19 prevention or treatment in patients.Competing Interest StatementK.G. is the director of ArtemiLife, Inc. K.G. and P.H.S. have a significant financial stake in ArtemiFlow GmbH, that is a shareholder in ArtemiLife, Inc. All other authors have no competing/conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Details

show
hide
Language(s): eng - English
 Dates: 2021-09-082021
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: DOI: 10.1186/s12985-021-01651-8
DOI: 10.1101/2021.02.14.431122
BibTex Citekey: Nie2021.02.14.431122
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Virology Journal
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: BioMed Central
Pages: - Volume / Issue: 18 Sequence Number: 182 Start / End Page: - Identifier: ISSN: 1743-422X

Source 2

show
hide
Title: bioRxiv
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Cold Spring Harbor : Cold Spring Harbor Laboratory
Pages: - Volume / Issue: - Sequence Number: 2021.02.14.431122 Start / End Page: - Identifier: ZDB: 2766415-6